ClinicalTrials.gg
CompletedNCT05392452CLABUpdated Jan 17, 2024

Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB)

An interventional study of CamAPS HX and Standard insulin therapy in Perioperative Hyperglycaemia, Insulin Therapy and Elective Surgery, sponsored by Lia Bally. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Lia Bally · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Liver Diseases with a site in Switzerland — 5 open to participants now, 6 under way, 2 of them phase 3. Liver Diseases · Switzerland.

Enrollment
10th of 15
38 · median 80
Started
2022
with 1 other
No phase
4 of 20
1 open now
Registered
18th of 20
by date

Among the 20 studies in Liver Diseases with a site in Switzerland, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 with no phase, and was the 18th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

5 of the 20 studies in Liver Diseases with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Liver Diseases with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy, safety and usability of perioperative fully-automated closed-loop insulin delivery versus standard insulin therapy in patients with diabetes other than type 1 diabetes undergoing elective major abdominal surgery.

Read the detailed description

The prevalence of diabetes and hyperglycaemia in surgical patients is rising and associated not only with greater complication rates, length of stay, morbidity and mortality rates, but also increased hospital costs and readmission rates. Due to the complex interaction of organs involved in glucose homeostasis (e.g. liver, pancreas) and the frequent need for nutrition support, patients undergoing major abdominal surgery are particularly prone to develop dysglycaemia. While there are guidelines for perioperative glucose management, implementation is challenging and inconsistent. Main reasons are lack of resources, clinical inertia based on fear of hypoglycaemia and multiple handovers between teams.

Closed-loop glucose control represents an emerging diabetes treatment modality that autonomously adjusts insulin delivery according to continuously measured glucose levels. The use of fully automated closed-loop insulin delivery may represent an easy-to-adopt approach for safe and effective perioperative diabetes management. In previous work, the investigators demonstrated that fully closed-loop insulin delivery in adults with type 2 diabetes undergoing various elective surgeries (abdominal, vascular, neurologic, orthopaedic, thoracic) improved glycaemic control by increasing time spent in the glycaemic target range, lowering mean sensor glucose and glycaemic variability without increasing the risk of hypoglycaemia.

In this follow-up trial the investigators will focus on patients undergoing major elective abdominal surgery to further explore the potential of the fully automated closed-loop approach to accommodate the complex needs of this population. Involvement of a second study centre and hospital staff for device management will further allow to assess the usability of the fully closed-loop system for larger multi-centre clinical trials as well as readiness to use the approach in usual clinical care.

03

Conditions studied

  • Perioperative Hyperglycaemia
  • Insulin Therapy
  • Elective Surgery
  • Closed-Loop Glucose Control
  • Artificial Pancreas
  • Liver Diseases
  • Diabetes Mellitus, Type 2
  • Colon Disease
  • Gastric Disease
  • Pancreatic Disease

Keywords

  • Perioperative Hyperglycaemia
  • Insulin Therapy
  • Elective Surgery
  • Closed-Loop Glucose Control
  • Artificial Pancreas
  • Liver Diseases
  • Diabetes Mellitus, Type 2
  • Colon Disease
  • Gastric Disease
  • Pancreatic Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or over
  • Pre-existing or anticipated (surgery-induced) diabetes other than type 1 diabetes
  • Expected to require insulin treatment in the perioperative period
  • Planned for elective major abdominal surgery at the University Hospital Bern or Basel expected to last ≥ 90 minutes, defined as colorectal, pancreatic, gastric (except bariatric surgery) and hepatic (≥ 2 segments) surgery

Exclusion criteria

Exclusion Criteria:

  • Physical or psychological condition likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Likely discharge earlier than 72 hours
  • Known or suspected allergy to insulin used in this clinical trial
  • Type 1 diabetes
  • Pregnancy, planned pregnancy, or breast feeding
  • Lack of safe for female participants of for the entire study duration (medically reliable method of contraception are considered oral, injectable, or implantable contraceptives, intrauterine contraceptive devices, or any other methods judged as sufficiently reliable by the investigator in individual cases).
  • Medically documented allergy towards the adhesive (glue) of plasters or unable tolerate tape adhesive in the area of sensor placement
  • Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor
  • Illicit drug abuse or prescription drug abuse
  • Incapacity to give
  • Not willingness to wear study devices 24/7
  • Not literate in German
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Closed-loop insulin therapy

    Intervention: Use of a fully-automated closed-loop insulin delivery system from day of admission until hospital discharge (or maximum 20 days).

    Device: CamAPS HX

  • Active comparator
    Standard insulin therapy

    The control group will receive insulin therapy in accordance with local practice. The insulin regimen during the study period may involve subcutaneous and/or insulin intravenous insulin administration. The modality of insulin treatment, dose adjustment and frequency of glucose monitoring will be at the discretion of the clinical team. No active treatment optimisation will be undertaken by the study team. Participants in the control group will be fitted with the identical study CGM system. The CGM system will be blinded upon hospital admission.

    Drug: Standard insulin therapy

Interventions

  • DeviceCamAPS HX

    Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.

  • DrugStandard insulin therapy

    Standard insulin therapy according to local clinical practice.

06

What researchers measure

Primary outcomes

  1. The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

Secondary outcomes

  1. Proportion of time spent with sensor glucose values above target (> 10.0 mmol/L)

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  2. Proportion of time spent with sensor glucose <3.0 mmol/L

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  3. Proportion of time spent with sensor glucose < 3.9 mmol/L

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  4. Average of sensor glucose level

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission or until a maximum of 20 days following surgery

  5. Proportion of time spent with sensor glucose below target (< 5.6 mmol/L)

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  6. Standard deviation of sensor glucose levels

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission or until a maximum of 20 days following surgery

  7. Coefficient of variation of sensor glucose levels

    The outcome is based on sensor glucose levels

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  8. Total daily insulin dose

    Insulin dose received by the patients in units/24h

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  9. Post-surgery comorbidity

    Assessed using the Comprehensive Complication Index (CCI)

    Time frame: Assessed at 30 days following surgery

  10. Length of hospital stay

    Assessed based on the information in electronic health records

    Time frame: Up to 20 days

  11. Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)

    Assessed based on the information from device manufacturers, hospital administration system and standard external sources for healthcare utilisation unit costs.

    Time frame: Assessed from hospital admission until a maximum of 30 days following surgery

Other outcomes

  1. Number of severe hypoglycaemia (< 2.2 mmol/L)

    Based on point-of-care capillary measurements. This is a safety outcome.

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

  2. Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L)

    Based on point-of-care capillary measurements. This is a safety outcome

    Time frame: Assessed from hospital admission until a maximum of 20 days following surgery

07

Study locations

2 sites
  • Anaesthesiology, University Hospital Basel
    Basel, 4031, Switzerland
  • Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital
    Bern, 3010, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2023, 14 months.

Of 122 non-industry interventional studies with no phase under Liver Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 14 months is below that.

Counting every sponsor, half of 135 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
May 26, 2022
StartActual
Aug 9, 2022
Primary completionActual
Oct 16, 2023
CompletionActual
Nov 13, 2023
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05392452
Lead sponsor
Lia Bally
Responsible party
Lia Bally (Head of Nutrition, Metabolism and Obesity and Head of Research, Insel Gruppe AG, University Hospital Bern) — Sponsor-investigator
First posted
May 26, 2022
Start date
Aug 9, 2022
Primary completion
Oct 16, 2023
Completion
Nov 13, 2023
Last update
Jan 17, 2024

Study contacts

Lia Bally, MD PhD
principal investigator · Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University, Unviersity of Bern
Thierry Girard, MD
principal investigator · Anaesthesiology, University Hospital Basel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion